Abstract:The mitochondrial DNA (mtDNA) 12S rRNA is a hot spot for mutations associated with both aminoglycoside-induced and nonsyndromic hearing loss. Of those, the homoplasmic A1555G and C1494T mutations at a highly conserved decoding region of the 12S rRNA have been associated with hearing loss. These two mutations account for a significant number of cases of aminoglycoside ototoxicity. The A1555G or C1494T mutation is expected to form novel 1494C-G1555 or 1494U-A1555 base-pair at the highly conserved A-site of 12S rRNA. These transitions make the secondary structure of this RNA more closely resemble the corresponding region of bacterial 16S rRNA. Thus, the new U-A or G-C pair in 12S rRNA created by the C1494T or A1555G transition facilitates the binding of aminoglycosides, thereby accounting for the fact that the exposure to aminoglycosides can induce or worsen hearing loss in individuals carrying these mutations. Biochemical characterization demonstrated an impairment of mitochondrial protein synthesis and subsequent defects in respiration in cells carrying the C1494T or A1555G mutation. Furthermore, the growth defect and impairment of mitochondrial translation in DMEM medium in the presence of high concentration of paromomycin or neomycin were observed in cell lines carrying the A1555G or C1494T mutation as compared to the average rate in control cell lines. These observations provide the direct genetic and biochemical evidence that the A1555G or C1494T mutation is a pathogenic mtDNA mutation associated with aminoglycoside-induced and nonsyndromic hearing loss. Therefore, these data provide valuable information and technology to predict: (1) which individuals are at risk for ototoxicity, (2) to improve the safety of aminoglycoside antibiotic therapy; and (3) eventually to decrease the incidence of deafness.

Finding Ways to Solve or Prevent Aminoglycoside-Induced Ototoxicity?

A Biochemical Basis for the Inherited Susceptibility to Aminoglycoside Ototoxicity

Mitochondrial DNA mutations associated with aminoglycoside induced ototoxicity

Aminoglycoside Ototoxicity: Prevention in Sight?

Prevalence of Mitochondrial 12s Rrna Mutation Associated with Aminoglycoside Ototoxicity

Mitochondrial DNA Mutations Associated with Aminoglycoside Ototoxicity

Mechanism and Prevention of Ototoxicity Induced by Aminoglycosides

Interaction of Aminoglycosides with Human Mitochondrial 12S Rrna Carrying the Deafness-Associated Mutation

Genetic Factors in Aminoglycoside Toxicity

Pharmacogenetics of aminoglycoside-related ototoxicity: a systematic review

Damaging Effects of Aminoglycoside Antibiotics on Cochlear Spiral Ganglion Neurons

Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic.

Potentiating aminoglycoside antibiotics to reduce their toxic side effects

Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype

[Ototoxic mechanism of aminoglycoside antibiotics--role of glutaminergic NMDA receptors]

Mechanisms and otoprotective strategies of programmed cell death on aminoglycoside-induced ototoxicity

Mechanisms and Pharmacokinetic/pharmacodynamic Profiles Underlying the Low Nephrotoxicity and Ototoxicity of Etimicin

P2X7 receptor is required for the ototoxicity caused by aminoglycoside in developing cochlear hair cells

PGC-1α-mediated Imbalance of Mitochondria-Lipid Droplet Homeostasis in Neomycin-Induced Ototoxicity and Nephrotoxicity

Susceptibility of immature spiral ganglion neurons to aminoglycoside-induced ototoxicity is mediated by the TRPV1 channel in mice

Research Advances in Prevention &cure of Ototoxicity Caused by Aminoglycoside Antibiotics Using Traditional Chinese Medicines